Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future

Diabetes mellitus (DM) is a chronic metabolic disease characterized by hypergly-cemia. Type 2 diabetes (T2DM) accounting for 90% of cases globally. The worldwide prevalence of DM is rising dramatically over the last decades, from 30 million cases in 1985 to 382 million cases in 2013. It’s estimated...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of diabetes Vol. 10; no. 8; pp. 446 - 453
Main Authors Dogruel, Hakan, Balci, Mustafa Kemal
Format Journal Article
LanguageEnglish
Published Baishideng Publishing Group Inc 15.08.2019
Subjects
Minireviews
Online AccessGet full text

Cover

More Information
Summary:Diabetes mellitus (DM) is a chronic metabolic disease characterized by hypergly-cemia. Type 2 diabetes (T2DM) accounting for 90% of cases globally. The worldwide prevalence of DM is rising dramatically over the last decades, from 30 million cases in 1985 to 382 million cases in 2013. It’s estimated that 451 million people had diabetes in 2017. As the pathophysiology was understood over the years, treatment options for diabetes increased. Incretin-based therapy is one of them. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) not only significantly lower glucose level with minimal risk of hypoglycemia but also, they have an important advantage in themanagement of cardiovascular risk and obesity. Thus, we will review here GLP-1 RAsrole in the treatment of diabetes.
Bibliography:Corresponding author: Mustafa Kemal, MD, Doctor, Department of Internal Medicine, Antalya Ataturk State Hospital, Anafartalar street, No. 100, Antalya 07070, Turkey. mkbalci@msn.com
Telephone: +90-505-4789010 Fax: +90-242-2496040
Author contributions: Dogruel H and Balci MK conceived of and designed the study; Dogruel H searched the literature and drafted the article; both authors revised the article and Balci MK gave final approval for the article.
ISSN:1948-9358
1948-9358
DOI:10.4239/wjd.v10.i8.446